Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Cervical Cancer Recurrent × RC48 antibody × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Ovarian Neoplasms 1 HER2-positive Metastatic Breast Cancer 1 HER2-low Breast Cancer 1 Cervical Cancer Recurrent 1

Interventions

tislelizumab 1 RC48 antibody 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06063018 2023-10-02

RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer

Peking Union Medical College Hospital

Phase 2 Recruiting

Cervical Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡